Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Charity L. Atkins
Observed names:
C. Atkins,
Charity Atkins
Institution:
GlaxoSmithKline (United States)
Observed institutions:
GlaxoSmithKline (United Kingdom),
Bristol-Myers Squibb (United States),
GlaxoSmithKline (United States)
OpenAlex ID:
A5113871544
Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1 H -indol-5-yl)-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)
2012
·
Jeffrey M. Axten
, Jesús R. Medina
, et al.
·
Journal of Medicinal Chemistry
·
680
Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity
2013
·
Charity Atkins
, Qi Liu
, et al.
·
Cancer Research
·
487
Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development
2013
·
Jeffrey M. Axten
, Stuart P. Romeril
, et al.
·
ACS Medicinal Chemistry Letters
·
253
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2009
·
Peter Sabbatini
, Susan Korenchuk
, et al.
·
Molecular Cancer Therapeutics
·
105
PDF
Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
2009
·
Peter Sabbatini
, Jason L. Rowand
, et al.
·
Clinical Cancer Research
·
90
PDF
In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor
2020
·
Aidan G. Gilmartin
, Arthur Groy
, et al.
·
Haematologica
·
83
PDF
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity
2008
·
Stanley D. Chamberlain
, Anikó M. Redman
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
64
In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate
2006
·
Christopher P. Regan
, Audrey A. Wallace
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
41
Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase
2008
·
Stanley D. Chamberlain
, Joseph W. Wilson
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
34
Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)
2008
·
Kyle A. Emmitte
, Brian J. Wilson
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
32
Cloning and expression of rat coagulation factor VII
2003
·
Shobha Seetharam
, Kathleen Murphy
, et al.
·
Thrombosis Research
·
10
Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo
2009
·
Sridhar K. Rabindran
, Peter Sabbatini
, et al.
·
Cancer Research
·
3
GSK2967901A, a novel small molecule SIRT1 activator for the topical treatment of psoriasis
2017
·
J. Ellis
, M. Seefeld
, et al.
·
Journal of Investigative Dermatology
·
2
Supplementary Data from Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
2023
·
Peter Sabbatini
, Jason L. Rowand
, et al.
Supplementary Figure 6 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Supplementary Figure 8 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Supplementary Figure 5 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Data from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
PDF
Data from Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
2023
·
Peter Sabbatini
, Jason L. Rowand
, et al.
PDF
Data from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
PDF
Data from Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
2023
·
Peter Sabbatini
, Jason L. Rowand
, et al.
PDF
Supplementary Figure 2 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Supplementary Figure 7 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Supplementary Tables and Figure Legends from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Supplementary Figure 3 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
2023
·
Peter Sabbatini
, Susan Korenchuk
, et al.
Show more works
View as search
Works count:
33
Citation count:
1,884
H-index:
10
I10-index:
11
Year
Topic
Type